Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $641K | $2.46M | $2.45M | $2.70M | $2.71M | $2.70M | $2.70M | $1.34M | — | $2.00M |
| Revenue growth | — | 283.2% | -0.3% | 10.4% | 0.3% | -0.3% | 0.0% | -50.4% | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | $13.0K |
| Gross margin | — | — | — | — | — | — | — | — | — | 0.7% |
| Operating income | -$10.0M | -$10.8M | -$13.5M | -$14.6M | -$11.8M | -$24.2M | -$40.6M | -$15.8M | -$12.8M | -$15.1M |
| Operating margin | -1561.6% | -438.6% | -552.3% | -541.3% | -433.8% | -896.2% | -1502.0% | -1176.8% | — | -754.4% |
| Net income | -$11.0M | -$10.5M | -$12.7M | -$14.4M | -$11.5M | -$23.0M | -$36.6M | $5.09M | -$19.1M | $64.0M |
| Net margin | -1710.5% | -426.7% | -519.7% | -531.1% | -424.8% | -850.5% | -1352.6% | 379.7% | — | 3202.5% |
| EPS (diluted) | $0.87 | $0.79 | $0.86 | $0.82 | $0.56 | $0.78 | -$0.94 | $0.14 | -$0.48 | $1.50 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.66M | -$5.83M | -$14.7M | -$12.9M | -$12.4M | -$21.2M | -$27.9M | -$10.3M | -$8.41M | -$9.14M |
| Capital expenditures | $9.00K | $7.00K | $5.00K | $15.0K | $82.0K | $375K | $496K | $254K | $18.0K | $9.00K |
| Free cash flow | $4.65M | -$5.84M | -$14.7M | -$13.0M | -$12.5M | -$21.6M | -$28.4M | -$10.5M | -$8.43M | -$9.15M |
| Share buybacks | — | — | — | — | — | — | — | — | $2.48M | $4.74M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.91M | $3.97M | $5.00M | $3.33M | $19.3M | $77.2M | $40.5M | $9.05M | $54.4M | $45.9M |
| Total assets | $42.8M | $38.7M | $47.4M | $34.7M | $44.6M | $178M | $162M | $221M | $155M | $231M |
| Long-term debt | — | — | $11.4M | $9.66M | — | — | $25.0K | — | — | — |
| Shareholders' equity | $26.2M | $19.2M | $31.1M | $19.4M | $32.9M | $166M | $152M | $164M | $146M | $200M |
| Retained earnings | -$46.0M | -$56.5M | -$69.2M | -$81.1M | -$92.6M | -$127M | -$163M | -$158M | -$177M | -$123M |
| Shares (wtd avg diluted) | 13.2M | 13.7M | 17.4M | 17.4M | 23.7M | 38.2M | 39.0M | 40.6M | 40.9M | 42.4M |
Every figure is extracted from ORAMED PHARMACEUTICALS INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.